Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06111235 · ClinicalTrials.gov registry record · Phase 3
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
A Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by CG Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT06111235 is a Phase 3 study of Bladder Cancer and Urothelial Carcinoma that is active but no longer recruiting, run by CG Oncology. The registered enrollment target is 367 participants, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06111235, a Phase 3 study of Bladder Cancer and Urothelial Carcinoma, is active but no longer recruiting, sponsored by CG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Conditions Studied
Interventions
- DRUG Cretostimogene Grenadenorepvec
- OTHER n-dodecyl-B-D-maltoside
Study Locations (20)
California
- Michael G. Oefelein MD Clinical Trials - Bakersfield
- USC/Keck Department of Urology - Los Angeles
- Tower Urology - Los Angeles
- Sun Kim Urology - Orange
- University of California Irvine Medical Center (UCIMC) - Orange
- University of California Davis Cancer Center - Sacramento
- Stanford University School of Medicine - Stanford
Florida
- Advanced Urology Institute - Daytona Beach
- Mayo Clinic Cancer Center - Jacksonville
- Lakeland Regional Health - Lakeland
- Advanced Urology Institute, LLC - Largo
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic - Scottsdale
- Arizona Institute of Urology PLLC - Tucson
Colorado
- Colorado Clinical Research - Aurora
- Urology Associates, PC - Lone Tree
Alabama
- Urology Centers of Alabama PC - Homewood
Arkansas
- Arkansas Urology PA - Little Rock
Connecticut
- Hartford HealthCare Medical Group - Hartford
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06111235
The ClinicalTrials.gov registry entry for NCT06111235 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,752-participant average among 175 other Bladder Cancer trials with a reported enrollment target (97% lower). The listed sponsor is CG Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cretostimogene Grenadenorepvec is the first listed.
NCT06111235 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06111235 about?
NCT06111235 is a clinical study titled "A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT". This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
What is the current status of trial NCT06111235?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2023-12-14. Estimated completion is 2029-02.
What conditions does trial NCT06111235 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Non-muscle Invasive Bladder Cancer, Urologic Cancer.
What interventions are being tested in trial NCT06111235?
The interventions under investigation include: Cretostimogene Grenadenorepvec (DRUG), n-dodecyl-B-D-maltoside (OTHER).
Who is sponsoring clinical trial NCT06111235?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06111235 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.